Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 91.05% is 101% above its 5-year average of -14670.29%, near the high end of its 5-year range (-1282700.00%–137089.47%).
100.12% above its 12-month average of -74357.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 44.75%.
GROSS MARGIN
91.05%
GROSS MARGIN AVG TTM
-74357.00%
GROSS MARGIN AVG 3Y
-120827.52%
GROSS MARGIN AVG 5Y
-14670.29%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.12%
CURRENT VS 3Y AVG
+100.08%
CURRENT VS 5Y AVG
+100.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.82%
median of 678 covered companies
CURRENT VS SECTOR MEDIAN
+128.65%
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$678.29M
Gross Margin
91.05%
TTM Avg
-74357.00%
3Y Avg
-120827.52%
5Y Avg
-14670.29%
Market Cap
$669.94M
Gross Margin
78.85%
TTM Avg
82.67%
3Y Avg
82.58%
5Y Avg
83.02%
Market Cap
$685.23M
Gross Margin
100.27%
TTM Avg
50.13%
3Y Avg
25.07%
5Y Avg
10.71%
Market Cap
$702.99M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
Market Cap
$646.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$743.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $678.29M | 91.05% | -74357.00% | -120827.52% | -14670.29% |
| MiMedx Group, Inc. (MDXG)vs › | $669.94M | 78.85% | 82.67% | 82.58% | 83.02% |
| Helus Pharma Inc. (HELP)vs › | $685.23M | 100.27% | 50.13% | 25.07% | 10.71% |
| Annexon, Inc. (ANNX)vs › | $694.64M | 0.00% | 0.00% | 0.00% | 0.00% |
| OmniAb, Inc. (OABI)vs › | $656.00M | -18.17% | 40.91% | 70.46% | 80.30% |
| Anteris Technologies Global Corp. (AVR)vs › | $702.99M | -16.57% | 15.14% | 17.91% | 27.64% |
| Aura Biosciences, Inc. (AURA)vs › | $646.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| Climb Bio, Inc. (CLYM)vs › | $642.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $743.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $715.38M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
91.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 44.75% |
| 2026-03-31 | 32.56% |
| 2025-12-31 | 97.67% |
| 2025-09-30 | -52386.67% |
| 2025-06-30 | -319573.33% |
| 2025-03-31 | -290607.14% |
| 2024-12-31 | -178300.00% |
| 2024-09-30 | -1282700.00% |
| 2024-06-30 | -637100.00% |
| 2024-03-31 | -99435.71% |
| 2023-12-31 | 137089.47% |
| 2023-09-30 | -24.06% |
| 2023-06-30 | -9767.78% |
| 2023-03-31 | -7420.81% |
| 2022-12-31 | -1624.14% |
| 2022-09-30 | -3688.00% |
| 2022-06-30 | -12506.17% |
| 2022-03-31 | -1489.91% |
| 2021-12-31 | -18952.17% |
| 2021-09-30 | -1059.59% |
| 2021-06-30 | -4.41% |
| 2021-03-31 | -538.45% |
| 2020-12-31 | 1390.17% |
| 2020-09-30 | -55.71% |
| 2020-06-30 | -332.70% |
| 2020-03-31 | -272.22% |
| 2019-12-31 | -508.82% |
| 2019-09-30 | -1635.93% |
| 2019-06-30 | -284.62% |
| 2019-03-31 | -284.62% |
| 2018-12-31 | -12.06% |
| 2018-09-30 | -12.06% |
| 2018-06-30 | -61.93% |
| 2018-03-31 | -61.93% |
